EGFR and non-small cell lung carcinoma: Despite initial responses to EGFR-TKIs in NSCLC patients, the efficacy of these drugs is often limited by the development of drug resistance (Yoshida et al., 2010; Seshacharyulu et al., 2012; Antonicelli et al., 2013; Kumarakulasinghe et al., 2015).